{
  "company": {
    "name": "Ambagon Therapeutics",
    "website": "https://ambagontx.com/",
    "record": "https://startuphistory.org/c/ambagontx.com"
  },
  "status": null,
  "history_since": "2026-11-13T11:02:00.212Z",
  "baseline": {
    "snapshot_id": "84bffefbf217ddbc0325c4890f1417299174dba2a9ce7b6e11e614d10a924f03",
    "observed_at": "2026-11-13T11:02:00.212Z",
    "headline": "The 14-3-3 Molecular Glue Company",
    "description": "Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conve",
    "evidence": "https://www.ambagontx.com/",
    "evidence_kind": "live_capture",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-13T11:02:00.212Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2026-11-13T11:02:00.212Z",
      "variants": [
        {
          "headline": "The 14-3-3 Molecular Glue Company",
          "subhead": "Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conve",
          "observed_at": "2026-11-13T11:02:00.212Z",
          "evidence": "https://www.ambagontx.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "The 14-3-3 Molecular Glue Company",
      "subhead": "Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conve",
      "from": "2026-11-13T11:02:00.212Z",
      "to": "2026-11-13T11:02:00.212Z",
      "captures": 1,
      "evidence": "https://www.ambagontx.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "on": "2026-11-13T11:02:00.212Z"
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "same_space": [
    {
      "name": "Apogee Therapeutics",
      "record": "https://startuphistory.org/c/apogeetherapeutics.com",
      "basis": "description_similarity",
      "category": null
    },
    {
      "name": "Actym Therapeutics",
      "record": "https://startuphistory.org/c/actymthera.com",
      "basis": "description_similarity",
      "category": null
    },
    {
      "name": "Myricx Bio",
      "record": "https://startuphistory.org/c/myricxbio.com",
      "basis": "category",
      "category": "Antibody-drug conjugates for cancer"
    },
    {
      "name": "Axcynsis Therapeutics",
      "record": "https://startuphistory.org/c/axcynsis.com",
      "basis": "category",
      "category": "Antibody-drug conjugates for cancer"
    },
    {
      "name": "Acceleron Pharma",
      "record": "https://startuphistory.org/c/acceleronpharma.com",
      "basis": "category",
      "category": "Antibody-drug conjugates for cancer"
    },
    {
      "name": "Allink Biotherapeutics",
      "record": "https://startuphistory.org/c/allinkbio.com",
      "basis": "category",
      "category": "Antibody-drug conjugates for cancer"
    }
  ],
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Ambagon Therapeutics” company record, https://startuphistory.org/c/ambagontx.com"
}